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Background: Cancer represents heterogeneous and aberrantly proliferative manifestations composed of (epi)
genetically and phenotypically distinct cells with a common clonal origin. Cancer stem cells (CSC) make up a rare
subpopulation with the remarkable capacity to initiate, propagate and spread a malignant disease. Furthermore,
CSC show increased therapy resistance, thereby contributing to disease relapse. Elimination of CSC, therefore, is a
crucial aim to design efficacious treatments for long-term survival of cancer patients. In this article, we highlight the
nature of CSC and propose that phosphoproteomics based on unbiased high-performance liquid chromatography-
mass spectrometry provides a powerful tool to decipher the molecular CSC programs. Detailed knowledge about
the regulation of signaling processes in CSC is a prerequisite for the development of patient-tailored multi-modal
treatments including the elimination of rare CSC.
Main body: Phosphorylation is a crucial post-translational modification regulating a plethora of both intra- and
intercellular communication processes in normal and malignant cells. Small-molecule targeting of kinases has
proven successful in the therapy, but the high rates of relapse and failure to stem malignant spread suggest that
these kinase inhibitors largely spare CSC. Studying the kinetics of global phosphorylation patterns in an unbiased
manner is, therefore, required to improve strategies and successful treatments within multi-modal therapeutic
regimens by targeting the malignant behavior of CSC. The phosphoproteome comprises all phosphoproteins within
a cell population that can be analyzed by phosphoproteomics, allowing the investigation of thousands of
phosphorylation events. One major aspect is the perception of events underlying the activation and deactivation of
kinases and phosphatases in oncogenic signaling pathways. Thus, not only can this tool be harnessed to better
understand cellular processes such as those controlling CSC, but also applied to identify novel drug targets for
targeted anti-CSC therapy.
Conclusion: State-of-the-art phosphoproteomics approaches focusing on single cell analysis have the potential to
better understand oncogenic signaling in heterogeneous cell populations including rare, yet highly malignant CSC.
By eliminating the influence of heterogeneity of populations, single-cell studies will reveal novel insights also into
the inter- and intratumoral communication processes controlling malignant CSC and disease progression, laying the
basis for improved rational combination treatments.
Keywords: Cancer stem cells, Phospho-signaling, Kinases, Phosphoproteomics, Tumor cell heterogeneity* Correspondence: fritz.aberger@sbg.ac.at; c.huber@sbg.ac.at
†Equal contributors
Department of Molecular Biology, Cancer Cluster Salzburg, Paris-Lodron
University of Salzburg, Hellbrunner Strasse 34, 5020 Salzburg, Austria
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gruber et al. Cell Communication and Signaling  (2017) 15:12 Page 2 of 16Background
Cancer is caused by the accumulation of genetic and
epigenetic changes that eventually account for the unre-
stricted proliferative and metastatic capacity of malig-
nant cells [1, 2]. Despite of having a common cellular
and genetic ancestor, deep genome sequencing of cancer
cells together with histopathological and molecular
marker analyses revealed a surprising heterogeneity of
cancer cells within the tumor mass. Following a
Darwinian selection scheme, clonal evolution results in
dynamic changes of subclones, which can account for
disease progression and drug resistance in response to
therapy [3–5]. Notably, the malignant capacity of clonal
cancer cells differs considerably in terms of tumor initi-
ation, propagation, metastatic spread and therapy resist-
ance. In most - if not all malignancies - these highly
aggressive traits can be ascribed to the presence of rare
and self-renewing cancer cells. Since this rare subpopu-
lation displays several stem-like cell characteristics and
is likely to derive from long-lived tissue stem cells, these
cells are commonly - but not exclusively - referred to as
cancer stem cells [6, 7]. The terminology for self-
renewing cancer cells with tumor initiating and
maintaining properties is diverse, controversial, context-
dependent and research-field specific. Here, we will use
the term cancer stem cells (CSC) for rare self-renewing
malignant tumor cells that have the ability to initiate,
maintain and propagate heterogeneous malignancies
(for details about the terminology and nomenclature
of CSC see [8]).
Cancer stem cells and tumor heterogeneity
The hierarchical CSC model of malignant development
and growth is a result of numerous recent genetic, cellu-
lar and molecular analyses of cancer heterogeneity (see
below). However, the first evidence pointing to theFig. 1 Scheme of the hierarchical stem cell model in healthy and malignan
blue cells) in normal tissue results in the generation of a daughter stem cel
to terminally differentiated cells (shown as light blue cells) of the given tissu
and/or progenitor cells, leading to the escape from intracellular and extrac
uncontrolled tissue growth. Constant self-renewal and the production of h
stem cells (CSC). The CSC model in malignant tissue represents a hierarchic
to the tumor mass consisting of heterogeneous cancer cells with variable d
are more resistant to radiation- and chemotherapy calling for targeted appexistence of stem-like tumorigenic cells dates back at
least several decades. Kleinsmith and Pierse demon-
strated in 1964 that single embryonal carcinoma cells
within a teratocarcinoma can give rise to multiple cellu-
lar lineages [9]. By performing 1700 single cell grafts, of
which 43 formed teratocarcinomas composed of at least
14 different somatic tissues, this study provided experi-
mental support for the stem cell theory of cancer. The
basic concept of this model, however, has already been
hypothesized in 1907 by Max Askanazy, a Prussian path-
ologist, who speculated that based on histological simi-
larities between tumors and embryonic tissues, cancer
arises from cells with properties similar to those of the
early embryo [10]. Much has changed since then from
both a technical and mechanistic point of view, but the
basic concept of tumors arising from undifferentiated
stem-like cells has recently been supported for many
cancer entities, using sophisticated and state-of-the-art
transplantation and genetic tools. Together, these sem-
inal studies (for elaborate reviews see [6, 11, 12]) have
led to a hierarchical rather than stochastic model of ma-
lignant development and growth driven by self-renewing
cancer stem cells (Fig. 1).
The first evidence for clonal and stem cell-derived devel-
opment of malignancies in man came from a study with pa-
tients suffering from chronic myeloid leukemia (CML). In
1967, Fialkow et al. investigated females heterozygous for
the X-linked glucose-6-phosphate dehydrogenase (G-6-
PD), resulting in the expression of only one of the two en-
zyme types in a single cell. By analyzing the blood cells of
three female heterozygous G-6-PD patients, the team found
exclusive expression of only one allele of G-6-PD in all
CML cells of a patient, suggesting that the malignancy
arose from a single hematopoietic stem cell [13].
Nearly 20 years later, the existence and phenotypic
characterization of leukemia initiating CSC was reportedt tissue. a Asymmetric cell division of a stem cell (SC; depicted as dark
l as well as committed and dividing progenitor cells that can give rise
e. b Genetic and/or epigenetic alterations can transform stem cells
ellular control mechanisms that restrain aberrant cell proliferation and
eterogeneous malignant progeny is considered a hall mark of cancer
al organization, where rare self-renewing and long-lived CSC give rise
egree of differentiation and proliferative capacity (orange cells). CSC
roaches that eliminate CSC in multi-modal treatment strategies [134]
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[14]. The authors found that only the rare CD34+ CD38-
subpopulation of undifferentiated leukemic cells pos-
sesses self-renewing and leukemia initiating capacity.
Since this study was based on engraftment experiments
in immunocompromised NOD/SCID mice, the leukemia
initiating cells were termed SCID leukemia-initiating
cells (SL-IC). Although the first concepts of the hier-
archical CSC model were based on studies of leukemic
malignancies (reviewed in [15]), multiple evidence has
been provided since for the existence of CSC in numer-
ous solid tumors. The first report of CSC in a solid ma-
lignancy came from studies of primary breast cancer
samples. Al-Haji et al identified rare, undifferentiated
CD44+/CD24-/low cells as highly tumorigenic [16]. In this
study, the authors demonstrated that as few as 100
CD44+/CD24-/low cells were sufficient to initiate the
growth of tumors that could be serially passaged, each
time giving rise to heterogeneous tumors comprising
rare self-renewing CD44+/CD24-/low CSC and abundant
non-tumorigenic cells.
During the past years, numerous reports have identi-
fied and confirmed the existence of rare CSC in the ma-
jority of human malignancies including cancers of the
brain, the gastro-intestinal tract, skin and many other
tissues [16–21]. Notably, CSC not only account for
tumor initiation, growth and relapse in settings of min-
imal residual disease, dormancy and therapy resistance
[22–25], but also are able to trans-differentiate for
instance, into endothelial cells, thereby contributing to
the tumor vasculature and malignant growth of glio-
blastoma [26]. As for the molecular determinants of
CSC fate, it could be shown that the expression of a
particular combination of transcription factors can
reprogram non-CSC into CSC-like cells, analogous to the
reprogramming and induction of pluripotent stem cells.
In a glioblastoma model, expression of four factors,
POU3F2, SOX2, SALL2 and OLIG2 in non-CSC is suffi-
cient for the reprogramming of stem-like tumor-
propagating cells (TPCs) with an epigenetic landscape
comparable to the proper CSC population [27].
The notion that CSC are likely to derive from long-
lived tissue stem cells has been intensely studied in
transgenic mouse models suitable for genetic labeling of
stem cells and lineage tracing of stem cell progeny in a
defined genetic setting including selected cancer driver
mutations (for review see [28]). Such studies revealed,
for instance, rare Lgr5-positive intestinal crypt stem cells
with hyperactive Wnt signaling as those cells that fuel
the growth of intestinal adenomas. Like wild-type intes-
tinal stem cells, Lgr5 positive adenoma stem cells reside
in the bottom of the crypt niche, where they generate
aberrantly proliferating Lgr5-negative adenoma cells that
build the tumor mass [29, 30]. In line with a crucial rolein fueling tumor growth, selective depletion of intestinal
CSC resulted in rapid tumor regression, demonstrating
the therapeutic potential of direct CSC targeting, al-
though the relevance of these findings to human path-
ology and therapeutic relevance still remains to be
addressed in detail [31] (for a general concept of CSC
targeting see Fig. 2).
Deciphering the phosphoproteome of CSC for the
development of anti-CSC therapies
The highly malignant nature of CSC together with their
pivotal role in disease relapse calls for a detailed and
comprehensive understanding of the molecular pro-
cesses regulating CSC behavior. Since kinases frequently
represent the major effectors of oncogenic signals that
can be efficiently targeted by small molecule drugs, we
propose that the in-depth analysis of the phosphopro-
teome of CSC in combination with functional assays will
allow the identification of kinases that determine the
malignant phenotype of CSC. We consider this know-
ledge as essential prerequisite for the design of efficient
combination treatments to eradicate CSC. If embedded
in multimodal treatment regimens including immuno-
therapy, anti-CSC strategies are likely to significantly im-
prove the overall survival of cancer patients by reducing
malignant growth, metastatic spread, therapy resistance,
and relapse rates.
The detailed and comprehensive analysis of rare CSC
by -omics methods is a challenging endeavor, since CSC
represent only a rare subpopulation of the tumor mass,
posing severe constraints on the number of cells avail-
able for downstream investigations. The instrumental
setup for the analysis of minute samples, therefore, has
to be of sufficient sensitivity, particularly if it comes to
technologies such as phosphoproteomics, where only a
fraction of the respective protein molecules display post-
translational phosphorylation marks. Aside from the
technological challenges, the lack of universal and un-
ambiguous CSC markers suitable for CSC isolation
needs to be taken into account for the design of the iso-
lation procedure.
Enrichment of rare CSC by their characteristic immu-
nophenotype distinguishing CSC from non-CSC cells of
the tumor bulk has been widely used and successfully
applied. However, the choice and combination of surface
epitopes is often specific only to a particular malignant
entity and can result in the partial isolation of character-
istic subpopulations of CSC [32, 33].
As an alternative, the increased activity of aldehyde de-
hydrogenase (ALDH) and certain efflux pumps in CSC
allows to distinguish CSC from non-CSC. Increased
ALDH activity can be translated biochemically into the
generation of fluorescent signals. ALDH-positive cells
can then readily be quantified and isolated by flow-
Fig. 2 Cancer Stem Cells (CSC) display enhanced chemoresistance and account for metastases and disease relapse. A tumor typically consists of a
minority of CSC, which give rise to more differentiated cancer cells. These differentiated tumor cells represent the majority of cells in the primary
tumor, but have a limited self-renewal capacity. Untargeted therapy (e.g. chemotherapy) mainly affects highly proliferating non-CSC. Therapy
resistant CSC are spared and can subsequently lead to tumor regrowth and therapy resistance in the initially responding patient (middle panel).
Anti-CSC therapy prior to or together with untargeted therapy would hinder the tumors ability to regrow (right panel). Cancer cells with CSC
properties can leave the primary tumor via blood or lymphatic vessels and form metastases in distant organs (lower left panel)
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spectively. One of the first studies applying this strategy
identified a rare ALDH-positive subpopulation of breast
cancer cells with pronounced tumor-initiating potential
consistent with ALDH-positive cells with CSC character-
istics [34]. In addition, high level expression of ATP-
binding cassette transporter proteins endows CSC with
an efficient efflux detoxification machinery. Therefore,
incubation of cancer cells with a cell permeable fluores-
cent dye such as HOECHST 33342 results in rapid and
quantitative efflux of the dye in CSC while non-CSC re-
tain a high intracellular concentration of HOECHST
33342. When analyzed by flow cytometry, CSC appear
as dim population referred to as side population. Con-
sistent with the dim side population being rich in CSC,
HOECHST 33342 dim but not bright cells display high
tumor initiating capacity [35–37].
CSC enrichment based on the differential immuno-
phenotype or enzymatic activity of CSC and non-CSC is
frequently applied and well established for a variety of
cancer entities. However, none of these methods allows
the selective expansion of CSC to readily increase CSC
numbers to levels sufficient for unbiased global phos-
phoproteomics approaches. Compared to non-CSC, CSC
have a much higher intrinsic capacity for clonal growth
when cultured under specific in vitro conditions. Forinstance, growth of pancreatic cancer cells in 3-
dimensional matrix cultures results in the formation of
large, tumor-initiating spheres highly enriched for CSC
[38, 39]. The clonogenic growth properties of CSC can
therefore be used for the selective expansion of tumor-
initiating CSC yielding cell numbers sufficient for elab-
orate phosphoproteomics studies.
Phosphoproteome analysis of cancer and cancer
stem cells
The role of protein phosphorylation in the control of
cellular behavior has been well appreciated and intensely
studied for many years. Phosphorylation serves as one of
the most important post translational modifications
(PTMs) of proteins to operate and reversibly control sig-
naling [40]. Since phosphorylation is known to affect
processes such as cellular growth, cell division, and me-
tabolism, a dysfunction in protein phosphorylation can
promote the development of various diseases such as
cancer. Kinases catalyze the phosphorylation of serine,
threonine or tyrosine residues within proteins using
ATP as substrate. The requirement of precise control of
kinase activity for the integrity of an entire tissue or even
organism becomes evident by the fact that genetic
alterations in kinase signaling pathways are frequently
associated with the development and growth of cancer
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ledge of the phosphoproteome landscape of CSC is an
important prerequisite for the design of efficient targeted
therapies selectively blocking aberrantly active kinases
and the malignant traits of CSC, respectively.
Phosphoproteome analysis or phosphoproteomics is a
comprehensive technique analyzing the phosphopro-
teome of cells in a particular cellular state and biological
context. The phosphoproteome comprises all phospho-
proteins within a cell population or a single cell. Accord-
ing to Aebersold and Goodlett, phosphoproteomics tries
to reveal the “trinity of protein phosphorylation ana-
lysis”, which is “identification of the site of phosphoryl-
ation, identification of the kinase responsible for the
phosphorylation, and identification of the function and
role of this phosphorylation” [45]. In the past, two-
dimensional gel electrophoresis (2-DE) has been the
dominant analysis technique for analyzing the phospho-
proteome. 2-DE fractionates intact and undigested pro-
teins by separation of the proteins by charge and
molecular mass in two separate dimensions [46]. In par-
ticular, Phos-tag containing gels were developed, which
enhance the separation of phosphoproteins through in-
corporation of Mn2+ or Zn2+ ions into the gel, for select-
ive separation of phosphoproteins in SDS-PAGE gels.
Followed by immunoblotting, a map of phosphorylated
proteins can be created enabling the profiling of kinase
activity in vitro [47].
While 2-DE has represented the golden standard for
comprehensive proteome analysis for many years
[48],the more generic nature of high-resolution tandem
mass spectrometry coupled to one- or multidimensional
high-performance liquid chromatography (HPLC-MS/
MS) [49] meanwhile has superseded the 2-DE technique.
In the so called “shotgun (phospho) proteomics” ap-
proach, extracted proteins of a cell population are first
digested by a specific protease before being subjected to
HPLC-MS/MS for separation and detection. The break-
through in the technical development, which enabled
the use of HPLC-MS/MS as a comprehensive revelation
engine for proteins and peptides, was the invention of
soft ionization techniques such as ESI (electrospray
ionization) [50], which enable the direct mass spectro-
metric analysis of biological samples from liquid, often
aqueous solutions. Nowadays, mass spectrometry is the
primary identification and quantification tool for com-
prehensive phosphoproteomics [51, 52]. Moreover, iden-
tification technologies based upon the gas-phase
fragmentation of peptide ions [53] and the matching of
the resulting set of fragment ions with protein sequence
databases [54–56] have laid the ground for the high-
throughput identification and quantification of proteins
in proteomic samples, enabling the analysis of more than
10,000 proteins in a single 12-day experiment [57].HPLC-MS/MS workflow for phosphoproteomics
A typical experimental design of a phosphoproteomics
study first involves the isolation of the phosphoproteins,
which is done by cell lysis in a lysis buffer assuring phos-
phatase and protease inhibition. After a complex sample
preparation procedure of denaturation, reduction, and
alkylation, the isolated proteins are digested into pep-
tides. This is normally done by using proteases such as
trypsin, chymotrypsin, or LysC, which provide peptides
of a size highly suitable for mass spectrometric investiga-
tion [58]. Combinatorial approaches that complement
trypsin by multiple proteases help to overcome the
drawback of tryptic digestion, which often results in
missing particular cleavage sites, particularly in the case
of phosphorylation or other post translational modifica-
tions [59].
In contrast to the sample preparation in proteomics,
the workflow for phosphoproteomics has to be expanded
by procedures for phosphopeptide enrichment. Since the
complexity of the cellular proteome hinders the direct
analysis of phosphopeptides that are usually present
in concentrations much lower than their non-
phosphorylated analogues, further fractionation and
phosphopeptide enrichment is needed to investigate the
phosphoproteome. Different enrichment and fractionation
methods have been applied, which were recently reviewed
[51]. Typically, enrichment strategies rely on affinity chro-
matography taking advantage of the phosphate-specific
binding abilities of certain metal oxides [60] (titanium di-
oxide, tin oxide [61]) or of immobilized metal ions such as
Fe3+ [62] or Ga3+ [63]. The corresponding chromato-
graphic modes have been termed metal oxide affinity
chromatography (MOAC) or immobilized metal affinity
chromatography (IMAC).
Since the detection of phosphorylated tyrosines is
superimposed by the higher abundant serine and threo-
nine phosphorylations in conventional shotgun phos-
phoproteomics approaches, immunoprecipitation based
on phosphotyrosine antibodies has been implemented as
an alternative enrichment strategy. Thus, the targeted
enrichment of phosphorylated tyrosines prior to HPLC-
MS detection improves the coverage of the phosphopro-
teome, especially when focusing on tyrosine phosphoryl-
ation by tyrosine kinases [51, 64, 65].
Furthermore, multidimensional chromatographic sepa-
rations are usually applied for extensive fractionation of
(phospho-) peptides [66]. Thereby the sample complex-
ity is reduced and the instrument sensitivity is increased.
Since peptides may contain both acidic and basic side
chains, they can bear, depending on the pH of the solu-
tion, a positive or negative net charge, making them
amenable to both cation- and anion-exchange chroma-
tography [67]. Moreover, phosphorylation introduces a
negative charge, thereby increasing the negative or
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resulting in a more hydrophilic nature of the phospho-
peptides. Therefore, hydrophilic chromatographic separ-
ation techniques or combinations of charge-based/
hydrophilic interaction modes are applicable [68].
The most commonly applied methods for separation
in a first dimension are strong cation exchange chroma-
tography (SCX) [69–71] or reversed-phase HPLC at high
pH [72] besides electrophilic repulsion chromatography
(ERLIC) [73] or hydrophilic interaction chromatography
(HILIC) [74]. This first dimension is usually combined
with a final (ion-pair) reversed-phase (IP-RP) separation
before mass spectrometric detection via high-resolution
mass spectrometry (HRMS) [51]. Offering the advantage
of very high resolution and mass accuracy, high-
resolution hybrid mass spectrometers such as
quadrupole-time-of-flight (Q-TOF) [75], linear ion trap-
Orbitrap (LTQ-Orbitrap), or quadrupole-Orbitrap (Q-
Orbitrap) instruments [76] are the first choice in large-
scale phosphoproteomics approaches. These instruments
provide full scan spectra of intact peptides as well as
fragment spectra of selected peptide precursor ions,
which are then compared with databases for peptide
identification by means of suitable computational tools
[55, 56, 77]. Advantages and disadvantages of instru-
ments have been reviewed elsewhere [51, 78]. A short
summary of a typical phosphoproteomics workflow is
shown in Fig. 3.
Challenges of analyzing the phosphoproteome
Phosphoproteins and -peptides are bringing about spe-
cial instrumental and sample preparation challenges.
The availability of relatively high amounts of sample
required for untargeted phosphoproteome analysis,Fig. 3 Typical phosphoproteomics workflow. Each step in a phosphoprote
phosphoproteomic depth, which can ultimately restrict the biological insig
phosphoproteomics community to improve each step in this workflow con
greater speed and depth, but comprehensive phosphoproteome coverage
Publications © 2015typically in the range of 100 μg [68] to several milligrams
of protein, may be problematic, especially when trying to
analyze human material from biopsies [79]. This limita-
tion may be overcome by employing targeted analysis by
means of highly sensitive, mass spectrometry-based
selected- or multiple reaction monitoring (SRM or
MRM) methods [80]. Furthermore, Sequential Window
Acquisition of all Theoretical Fragment Ion Mass Spec-
tra (SWATH-MS) is evolving as a highly efficient global
(phospho) proteome quantification strategy [51] and
might facilitate the incorporation of tissue samples into
SWATH-MS proteome maps similar to biobanks [81].
Microfluidic approaches to single-cell phosphoprotein
analysis in a clinical context will be discussed in a separ-
ate section below.
Due to the sub-stoichiometric nature of protein phos-
phorylation, special sample preparation and phospho-
peptide enrichment steps are required, as mentioned
above. Besides, phosphopeptides provide significant diffi-
culties for the mass spectrometric analysis [52, 82].
Phosphopeptides show lower ionization efficiencies in
positive ionization mode due to ion suppression com-
pared to non-phosphorylated peptides [83]. In addition,
in the case of phosphoproteins, the labile phosphoryl
group can be easily lost during fragmentation. This leads
to an incident called neutral loss of 98 Da, which usually
produces a dominant fragment ion and has to be consid-
ered for the identification of the peptides. Different frag-
mentation techniques have been applied and combined
to improve the phosphopeptide identification such as
collision-induced dissociation (CID) [84], higher-energy
collision-induced dissociation (HCD), and electron-
transfer dissociation (ETD) [85], but until now there is
no universally applicable technique [86]. Furthermore, itomic experiment can contribute to limitations in reproducibility and
ht obtained from an experiment. Concerted efforts in the
tinue to advance our ability to sample the phosphoproteome with
remains out of reach. Reproduced from [51] with permission of ACS
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corresponding amino acid residue. This phosphosite
localization can be even more important and challenging
than the peptide identification itself craving for an ap-
propriate algorithm [87].
Moreover, tyrosine phosphorylation occurs 100–1000
times less than Ser/Thr phosphorylation, which requires
phosphotyrosine-specific enrichment strategies as de-
scribed above [51]. The study of tyrosine phosphoryl-
ation is important in unraveling signaling mechanisms
connected to malignancies such as cancer, especially be-
cause the majority of FDA approved kinase inhibitors
applied in tumor therapy target tyrosine kinases [88, 89].
In addition to the requirement of sophisticated and
state-of-the-art technologies, also the dynamic nature of
phosphorylation requires careful avoidance of enzymatic
or chemical dephosphorylation by means of phosphatase
inhibitors, making the analysis a challenging task [90].
Phosphorylation events are time dependent and thus
phosphoproteomics can only provide a snapshot of the
particular condition.Quantification of changes in phosphoproteome
regulation
Quantification is essential to reveal changes in the phos-
phoproteome. It enlightens the proteins, which are sig-
nificantly regulated in the particular experimental
conditions in response to e.g. a defined treatment, and
helps to resolve signaling networks. There are different
quantification strategies applied for phosphoproteomic
approaches mainly including isotope-labeling and label-
free methods. The most dominant techniques focus on
labeling of peptides or proteins mostly with stable iso-
topes, which can be readily distinguished by mass spec-
trometry [91]. Stable isotope labeling by amino acids in
cell culture (SILAC) is a very common metabolic in vivo
labeling method before proteolytic digestion [92].
Thereby, during protein biosynthesis the cells incorpor-
ate isotope-labeled amino acids provided in the cell
culture medium or in the feed for animal models.
Peptides can also be isotope-labeled during the tryptic
digestion of proteins through incorporation of heavy
oxygen from H2
18O. Moreover, reductive dimethylation
labeling using regular or deuterium-labeled forms of for-
maldehyde and sodium cyanoborohydride is an efficient
post digestion labeling method applied for full MS quan-
tification by comparing extracted ion chromatogram
peak areas corresponding to the differently isotope-
labeled peptide species [93]. Isotope-labeling of proteins
or peptides can also be performed upon chemical deriva-
tization with isotope-labeled, mostly amino- or thiol-
reactive agents such as Isotope-coded Affinity Tags
(ICAT) [94] or Isotope-Coded Protein Labels (ICPL) [95].Finally, tags like isobaric tags for relative and absolute
quantitation (iTRAQ) [96], or tandem mass tags (TMT)
[97] can be used to quantify phosphopeptides by tandem
mass spectrometry [98]. Here, quantification is enabled
by tandem mass spectrometry (MS/MS) after fragmenta-
tion of the phosphopeptide upon generating reporter
ions to obtain ratios between controls and treatments.
One of the major advantages of isobaric labeling is the
economization of measurement time and expense by
merging of multiple (up to ten) samples. A more time
consuming but attractive method for quantitative phos-
phoproteomics is label-free quantification of peptide sig-
nals in independent HPLC-MS/MS analyses [99, 100].
This is especially interesting for phosphoproteomics,
since it does not require any further labeling and thus
saves costs and prevents interferences with the phos-
phate group of the peptides. Nevertheless, there is a
strong requirement for careful experimental design and/
or normalization strategies in order to obtain compar-
able signal intensities [101].
Phosphoproteomic applications for the analysis of
cancer cells
HPLC-MS/MS based phosphoproteomics represents a
discovery driven approach, which can help to track new
drug targets and illuminate up- and downstream signal-
ing molecules. Furthermore, phosphoproteomics can
help to give new insights into phosphorylation networks
and kinase-substrate interactions.
The human epidermal growth factor (HER) family of
receptor tyrosine kinases was one of the first targets,
which was addressed by phosphoproteomic analysis. The
first studies analyzed changes in phosphorylation focus-
ing on the analysis of phosphoproteins after enrichment
by phosphotyrosine antibodies to examine the effect of
epidermal growth factor (EGF) stimulation [102].
Although these studies provided insight into activation
profiles of key proteins involved in epidermal growth
factor receptor (EGFR) signaling and other unknown
downstream proteins, they lack a global view to the
phosphoproteome.
One of the first large-scale analyses of tyrosine kinase
activity in lung cancer was performed in 2007 by Rikova
et al., who identified 50 tyrosine kinases and over 2500
downstream substrates [103]. They confirmed well-
known tyrosine kinases involved in oncogenic signaling
such as EGFR and hepatocyte growth factor receptor
(HGFR or c-Met). Furthermore, it was shown that acti-
vated forms of anaplastic lymphoma kinase (ALK) and
receptor tyrosine kinase (ROS) can be identified in lung
cancer cells, in particular in non-small cell lung cancer
cell lines (NSCLC). A first deep and extensive view of
tyrosine kinase activity and downstream signaling net-
works was described.
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and more important especially in the area of cancer
research. The first study elucidating temporal dynam-
ics of phosphorylation upon growth factor stimulation
was performed by Olsen and Mann in 2006. Accord-
ing to their discoveries, EGF-signaling is regulated by
phosphorylation of a variety of transcriptional regula-
tors, amongst others signal transducer and activator
of transcription 5 (STAT5), transcription factor MYC,
and transcription factor JUND, within a short time
frame of 20 min. By following regulatory changes over
a particular time frame, signaling outcomes could be
connected to responsible upstream or downstream
events [104].
Quantitative phosphoproteomic profiling was already
used to portrait different tumorigenic signaling path-
ways, to compare different tumor entities and to analyze
the heterogeneity of tumors. Only recently Schweppe
et al. applied a Super-SILAC approach for decoding glo-
bal phospho-signaling networks in NSCLC patient sam-
ples. They were able to differentiate between different
types of non-small cell lung cancer populations due to
changes in particular oncogenic drivers such as epider-
mal growth factor receptor 2 (ErbB2) and RAF/MEK/
ERK signaling [105]. The RAF/MEK/ERK signaling is
important for cellular growth, malignant transformation
and drug resistance [106]. The regulation of stromal
cells by oncogenic KRAS (Kirsten rat sarcoma viral
oncogene homolog) in pancreatic ductal adenocarcin-
oma (PDA) cells was demonstrated by Tape et al. [107].
They performed an innovative sample preparation
method called automated phosphopeptide enrichment
(APE), where magnetic TiO2 and Ti-IMAC microspheres
are used to enrich phosphopeptides by employing a
magnetic particle handling robot [108]. They investi-
gated the cell-autonomous and non-cell autonomous
signaling effects of oncogenic KRAS on the phosphopro-
teome of PDA. Thereby, a cell-autonomous activation of
ERK 1/2 was determined resulting in an induction of
Map kinase and cyclin dependent kinase motifs. Like-
wise, oncogenic KRAS was demonstrated in a quantita-
tive proteomic analysis to control PDA cells by
influencing the Sonic Hedgehog (SHH)-Smoothened
(SMO)-GLI axis of stromal cells. The stromal-driven
tumor cell phosphoproteome moreover differed from
the oncogenic KRAS regulated cell-autonomous phos-
phoproteome revealing reciprocal signaling of the
stromal cells. This evidence emphasizes the import-
ance of focusing on tumor heterogeneity in cancer
studies and therapy.
Phosphoproteomics and proteogenomics can help to
understand mechanisms of resistance to cancer thera-
peutics and predict efficacy or adverse reactions relevant
for personalized medicine. As a comprehensivetechnique, phosphoproteomics offers the opportunity to
study changes in the phosphorylation of targeted pro-
teins after treatment and thus can be used as an investi-
gation tool for pre-clinical and clinical investigations.
Thereby it can be used to improve and expand current
drug treatment systems [105] by tailoring medication for
therapy to individual responsiveness and tendency for
side effects. By applying phosphoproteomics on meta-
static castration-resistant prostate cancer (CRPC) mater-
ial, Drake and colleagues could identify phosphorylation
of key mediators in six major signaling pathways, includ-
ing the cell-cycle pathway, DNA repair pathway, AKT/
mTOR/MAPK pathway, and the nuclear receptor path-
way, which revealed potentially useful information for
patient stratification and targeted therapy [109].
Proteogenomics parses the relation of genetic alter-
ations to functional protein expression by comparison
and integration of RNA and DNA sequencing data and
(phospho) proteomics to infer their particular influence
on the resulting phenotype [110, 111]. In breast cancer,
the analysis of the phosphoproteome identified several
phosphorylated kinases and a G Protein-coupled recep-
tor cluster that could not be detected at the mRNA level
[110]. Previous proteogenomic characterization of high-
grade serous carcinoma (HGSC), which comprises the
majority of ovarian cancer cases, included phosphopep-
tide analysis and demonstrated the added value of pro-
tein phosphorylation data when correlating pathway
activity with patient survival [112]. Another proteoge-
nomic study characterized rectal cancer patients and
used proteomics data to prioritize candidate driver
genes [111].
In the past decade, the focus has shifted towards
the functional and temporal analysis of changes
within particular oncogenic pathways upon treatment
with tyrosine kinase inhibitors as potent cytostatic
drugs for the treatment of various cancers. Zhang
et al. examined the global phosphoproteome after
erlotinib treatment, a tyrosine kinase inhibitor for the
treatment of lung cancer. They utilized lung adeno-
carcinoma cell lines harboring mutations in the kinase
domain of EGFR, making them either sensitive or
resistant to erlotinib treatment. They compared phos-
phorylation events and canonical pathways enriched
in the sensitive or resistant cells [113]. Particular dif-
ferences in EGFR connected pathways and changes in
the phosphorylation patterns of regulatory proteins
such as phosphorylated AKT (pAKT) and pERK
(phospho-extracellular-signal regulated kinase) de-
pending on erlotinib treatment of the resistant or
sensitive cells were observed (Fig. 4). Their study
gives novel impressions of phosphorylation events
affected by erlotinib treatment and provides insights
into possible mechanisms of drug resistance.
Fig. 4 Phospho-sites identified in proteins of the RAS-RAF-MAPK and PI3K-AKT signaling pathway in a lung adenocarcinoma cell line harboring a
L858R mutation in the kinase domain of EGFR, which is reactive to treatment with erlotinib. Reproduced from [113] with permission from Wiley-
VCH © 2015
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ase 2 as a modulator of tamoxifen resistance in breast can-
cer. They treated MCF7 breast cancer cells for 6 months
with the selective estrogen-receptor modulator tamoxifen
or ethanol as a vehicle control in vitro. SILAC was used to
perform quantitative phosphoproteomic profiling based
on HPLC-HRMS. By systematically analyzing the 2189
identified phosphorylated proteins, the focal adhesion
pathway was identified as one of the most enriched signal-
ing pathways. Protein phosphorylation was significantly
elevated in the tamoxifen resistant cells. The 27 hyperpho-
sphorylated proteins included the focal adhesion kinases
FAK1 and FAK2 in the tamoxifen resistant breast cancer
cells. In ongoing investigations by using real-time PCR,
Western blot analyses, and immunofluorescence staining
the overexpression of FAK2 in tamoxifen resistant cells
was confirmed. Finally, siRNA knockdown of FAK2 sig-
nificantly reduced the proliferation of the MCF7-
tamoxifen resistant cells and thus confirmed the pivotal
role of FAK2 for tamoxifen resistance in these cells [114].CSC – an intricate challenge for proteomic and
phosphoproteomic profiling
CSC are of main interest both for biomedical research
and clinical therapy. As it has been introduced above,
CSC account for metastasis, relapse, and resistance to
cancer therapeutics in different cancer entities. Analyz-
ing CSC remains a challenge due to their low abun-
dance and the task to specifically isolate these cells
(see above).
Since phosphorylation patterns and dynamics are cru-
cial for the regulation of normal and malignant cellular
behavior, future studies are to focus on phosphoproteo-
mics to investigate cancer stem cell signaling. Proteomic
profiling has already been applied to different cancer
stem cell entities. In 2010, one of the first quantitative
profiling studies of pancreatic CSC was published by Dai
et al. They solved the problem of the limited number of
CSC gained from xenograft mouse models of primary
human pancreatic adenocarcinomas by applying a two-
dimensional approach [115] that combined capillary
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ation with nano reversed-phase HPLC-MS/MS followed
by label-free quantification [115]. With this approach,
they identified mitochondrial dysfunction as the top reg-
ulated pathway in the CSC population compared with
the bulk tumor group. Moreover, other pathways known
to be involved in cellular growth and proliferation such
as VEGF signaling were shown to be enriched in CSC.
Also, Interleukin signaling, Ras homologue gene family
member A (RhoA), and integrin signaling pertaining to
inflammatory and immunological pathways were found
to be associated with CSC communication. Their results
underline the connection between inflammation and
carcinogenesis.
Recently, the proteome of sonic hedgehog driven hu-
man medulloblastoma stem-like cells was analyzed be-
fore and after retinoic acid differentiation [116]. The
stem-like cells isolated from human infant medulloblas-
toma samples were further cultured as neurospheres in
selective medium. HRMS following HPLC separation de-
termined heat shock protein 70 as overexpressed in
stem-like cells. Furthermore, the nuclear factor kappa-
light-chain-enhancer of activated B-cells (NF-κB) com-
plex and tumor suppressor protein p53 were illuminated
as pivotal players for cancer and stemness networks. On-
going investigations showed that the phosphorylated p65
subunit of the NF-κB complex was highly expressed in
these cancer stem cells, thereby identifying new key bio-
logical players involved in cancer stem cell biology of
medulloblastoma.
To better understand dynamic signaling processes in
CSC, Nilsson et al. initiated the first quantitative phos-
phoproteomic analysis of glioblastoma stem cells in
2010. They scrutinized glioblastoma stem cells (GSC)
derived from human tumors and cultured them as neu-
rospheres. These cells were treated with the novel JAK2/
STAT3 phosphorylation inhibitor WP1193 and/or the
JAK/STAT3 activator IL-6 under normoxic and hypoxic
conditions [117]. Six different conditions were compared
by using TMT labeling prior to HILIC fractionation and
TiO2 enrichment. The separation was performed by RP-
HPLC and detection by HRMS resulting in a total of
3414 proteins detected. Subsequent data evaluation
linked 21 highly regulated proteins to STAT3, HIF1α
(hypoxia inducible factor 1 alpha) and IL-6 signaling.
Several phosphoproteins linked to metabolic changes
were observed under hypoxic conditions besides 11 pro-
teins connected to HIF1α. Mitogen-activated protein
kinase 1 (MAPK1)-expression in particular was increased
reflecting HIF1α activation. Comparing normoxic and
hypoxic conditions, they showed that hypoxic GSC were
less responsive and thus more resistant to treatment with
WP1193. Under treatment with WP1193 in combination
with IL-6 they observed increased Insulin-like growthfactor I (IGF1) signaling in both normoxic and hypoxic
cells which confirmed the modulatory role of IGF1 in glio-
blastoma proliferation and migration [118]. Even though
the effect of hypoxia on glioblastoma growth was well de-
scribed based on their data, this study did not focus on
the analysis of phosphorylation sites and kinase substrate
interactions. Thus, they could not enlighten the deeper
effect of different treatment conditions to the phosphoryl-
ation dynamics in glioblastoma stem cells.
Kozuka-Hata et al. addressed glioblastoma initiating
cells two years later by investigating the effect of EGF
stimulation on initiating cells from glioblastoma patients
[119]. They used SILAC for quantification and TiO2 col-
umns to enrich the phosphopeptides prior to HPLC-
MS/MS analysis. By searching against a human RNA
database, they identified a novel peptide encoded by
supervilin-like (LOC645954), which showed altered
phosphorylation patterns upon EGF stimulation in a
cell-type dependent manner. They started to look deeper
into phosphorylation sites and their influence on com-
munication and regulation of GSC. Out of 6073 phos-
phopeptides encoding 2282 phosphoproteins, 635
proteins belonging to the ErbB and mTOR signaling
were shown to be upregulated in these CSC.
Still, our understanding of CSC regulation via phos-
phorylation remains largely incomplete. Only recently,
the downstream signaling of stromal cell-derived factor
1 (SDF-1)/G protein-coupled receptor chemokine recep-
tor 4 (CXCR4) in breast CSC has been examined [120].
The critical role of CXCR4 for tumor progression has
already been known from O’Hayre et al., who examined
the CXCL12/CXCR4 signaling network in chronic
lymphatic leukemia (CLL) in 2010 but due to technical
limitations, this work lacked comprehensive phosphosite
analysis [121]. Yi et al. isolated CD44high/CD24low CSC
from human mammary epithelial cancer cells (HMLER)
and cultured them as tumor spheres. Phosphorylation
events induced by 10 min treatment with SDF-1 with or
without transient CXCR4 knockdown were compared.
Phosphorylation changes were observed in several pro-
teins with cell regulatory functions such as GTPase acti-
vating proteins and histone modification enzymes.
Furthermore, they more deeply analyzed phosphorylation-
affected kinases and phosphatases, among them ERK1
and serine/threonine-protein kinase 4 (PAK4), which
were already known to be involved in the SDF-1/
CXCR4 signaling cascade. PAK4 was already described
as being important for the development of breast can-
cer [122]. Besides, 44 kinases out of 50 at least 2-fold
elevated kinases detected have been not known to be
related to this signaling machinery before. Further-
more, 70 phosphosites of the 87 phosphosites detected
in these kinases were still undiscovered. By examining
kinase-substrates and phosphatase-substrates of 266
Fig. 5 Microfluidic approach to single-cell phosphoproteomics. a
The optical trap is used to move cells (green circles) from flow to
analysis chambers. Inset: bright-field image of an antibody spot
aligned within a chamber. Scale bar = 100 μm. b Single cells (green
circles) are lysed by the delivery of a single 6 ns pulse at λ = 1064 nm
10 μm above the center of the cell. (1) At sufficient irradiance the
medium breaks down to form a localized plasma; (2) An outwardly
propagating shockwave and an expanding cavitation bubble are
produced; (3) the cell is lysed due to shear stress from the expanding
cavitation bubble; and (4) cellular constituents are released into the
chamber. c Single cell protein levels are measured using an antibody
spot. Chamber volume is 4.6 nL and results in favorable kinetics. By
employing TIRF, only 10 fluorophores within 200 nm of the surface
are imaged, which are assumed to be antibody/antigen bound.
Reproduced from [129] with permission from the Royal Society
of Chemistry © 2011
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tiple upstream kinases were found to be mediated by
SDF-1/CXCR4 signaling. These were upstream kinases
such as Pyruvate dehydrogenase kinase 1 (PDK-1),
ERK1, GSK3 β for 5 phosphoproteins such as PKA
(protein kinase A) and NF-κB. Moreover, a MAPK
network downstream of SDF-1/CXCR4 signaling could
be created providing novel insights into the resulting
system-wide phosphorylation dynamics [120].
In spite of a remarkable progress over the decades
made in the field of CSC research, analyzing the global
phosphoproteome and phosphorylation dynamics of this
subpopulation of cells is still not routinely practicable.
CSC expansion by cell cultivation is mostly needed to
obtain enough material for the analysis, which, however,
can distort a realistic situation and reduce the clinical
relevance.
Single cell proteomics for CSC investigation
One of the major disadvantages of current phospho-
proteomics approaches is the need for relatively large
amounts of cells samples, i.e. in the range of several
million cells. This inevitably results in the study of
heterogeneous cell populations, where the protein
amount of each single cell and the respective phos-
phorylation pattern may vary considerably. Variability
in phosphorylation-dependent signaling can influence
the phenotype and quality of tumors, indeed it can be
a reason for the formation of CSC [123]. CSC and
bulk cancer cells are known to show inter- and intra-
tumoral heterogeneity with marked differences in
their malignant capacities. This versatility of a cancer
(stem) cell population can be influenced by the
microenvironment and/or intratumoral communica-
tion processes that induce different cell specific gene
expression states [124] (for reviews see [3, 125]).
Until now, there are still technical limitations to per-
form phosphoproteomics at the single-cell-level, with
sensitivity being the primary constraint [90]. For a com-
prehensive state-of-the-art phosphoproteomics approach
the protein amount of a single cell is too low. Thus, the
innovative approaches are based on the implementation
of microfluidic systems in combination with very sensi-
tive detection schemes of phosphoproteomics. In par-
ticular, lab-on-a-chip technologies should enable and
simplify single-cell phosphoproteomic analyses [126].
Wei et. al only recently reported the first single-cell
phosphoproteomics approach to study signaling dynamics
in glioblastoma with a focus on development of drug re-
sistance. They used the single-cell barcode chip technol-
ogy (SCBC) to investigate more than a dozen of proteins
and phosphoproteins [127, 128]. In this setup, one-cell
microchambers were used to isolate single cells as illus-
trated in Fig. 5 [129]. These microchambers were
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containing storage cavities, such that on-chip cell lysis
could be performed. Each microchamber could be covered
with a chip that featured an antibody-barcoded stripe
which was used to capture the released (phospho)
proteins. Detection of the (phospho)proteins was subse-
quently done by fluorescently labeled secondary antibodies
[130, 131]. Thereby activation of ERK- and proto-oncogene
tyrosine-protein kinase Src signaling was detectable
and linked to the cause of resistance to CC214-2 –
an mTOR kinase inhibitor [132].
However, this approach is far from being comprehen-
sive and unbiased. Antibody arrays are used to capture
and quantify the proteins and phosphoproteins of inter-
est. The barcode protein assay exhibited comparable dy-
namic ranges to commercially available ELISAs for
around 12 proteins [127]. Meanwhile the number of de-
tectable proteins was extended up to around 40 proteins
per cell. Nevertheless, this targeted concept using prior
knowledge about the tumor can hardly be compared
with the discovery-driven process of unbiased HPLC-
MS/MS based phosphoproteomics. Nevertheless, it can
be feasible for implementation into the clinics, since
only small amounts of material are needed and assays
can be customized easily. There have been many at-
tempts of combining this microfluidic principle with
mass spectrometry, then called Chip-MS (for a review
see [133]). These techniques are still in progress to be
automated and improved but they combine both advan-
tages of the downscaling feature of the microchip and
the sensitive and discriminative detection capabilities of
the MS instrument.
Conclusions
The highly malignant nature of rare CSC such as their
exquisite capacity to initiate and fuel tumor growth, to
seed metastases and their pronounced intrinsic resist-
ance to chemo- and radiation therapy – a frequent cause
for patients´ relapse - calls for efforts to decipher the
malignant code of the phosphoproteome. Understanding
the complex phospho-signaling landscape of CSC will
support the development of innovative multi-modal
treatments including small-molecule targeting of key
CSC kinases in combination with for instance, immuno-
therapy to significantly improve the overall long-term
survival of patients.
Experimental workflows offering sufficient sensitivity
and extensiveness for unbiased phosphoproteome
analysis represent a real challenge in the investigation of
signaling in heterogeneous populations of tumor cells.
Nevertheless, in the past two decades, significant
improvements in the detection techniques in terms of
detection limits and structural information have enabled
phosphoproteomic studies with very low amounts ofsample down to the single-cell level. Moreover, the
dynamic nature of phosphorylation itself provides chal-
lenges from the biological system, requiring very rapid
quenching and sample preparation pipelines. Examining
the phosphorylation events at single cell level is a desir-
able approach, but currently is restricted to the pre-
selection of candidate phosphoproteins.
Comprehensive HPLC-MS/MS phosphoproteomics
based on the analysis of single CSC represents an
innovative and illuminative approach to investigate
tumor initiating cells in great detail. In the future, with
customized, enhanced and improved instrumentation
this technique will likely become a routine part of mod-
ern clinical diagnosis and analysis as well as an essential
method in the area of precision oncology.
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